# UHC vs Cigna Drug Testing Policy Gap Analysis

**UHC Policy:** 2025R6005B  
**UHC Source:** [https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-reimbursement/COMM-Drug-Testing-Policy.pdf](https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-reimbursement/COMM-Drug-Testing-Policy.pdf)

**Cigna Policy:** R25 Drug Testing Billing Requirements  
**Cigna Source:** [https://static.cigna.com/assets/chcp/secure/pdf/resourceLibrary/clinReimPolsModifiers/R25_Drug_Testing_Billing_Requirements.pdf](https://static.cigna.com/assets/chcp/secure/pdf/resourceLibrary/clinReimPolsModifiers/R25_Drug_Testing_Billing_Requirements.pdf)  
**Cigna Coverage:** [https://static.cigna.com/assets/chcp/pdf/coveragePolicies/medical/mm_0513_coveragepositioncriteria_drug_test.pdf](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/medical/mm_0513_coveragepositioncriteria_drug_test.pdf)

**Analysis Date:** January 2026

---

## Summary Comparison Table

| # | Rule/Tactic | UHC | Cigna | Recommendation |
|---|-------------|-----|-------|----------------|
| 1 | Definitive Drug Class Limit | No limit - G0480-G0483 all covered | 7-8 drug class max; G0482, G0483 NOT covered | Consider drug class limits |
| 2 | G0659 Coverage | Covered as definitive test | Not covered or reimbursable | Evaluate G0659 medical necessity |
| 3 | Annual Frequency Limits | No annual limit specified | Industry practice: 12 presumptive/year | Consider annual limits |
| 4 | Presumptive Before Definitive | Not required - either can be billed | Presumptive recommended before definitive | Consider step-therapy approach |
| 5 | Pain Management Frequency | No specific frequency guidance | Random testing encouraged; routine testing flagged | Add frequency guidance |

---

## 1. Definitive Drug Class Limit

**Source Text Comparison**

| UHC (2025R6005B) | Cigna |
|------------------|-------|
| *"UnitedHealthcare will only allow one drug test within the presumptive Drug Class and one drug test within the definitive Drug Class per date of service."* All G0480-G0483 covered. | *"Cigna allows 8 definitive tests per date of service. G0482 and G0483 are not medically necessary (exceed 8 test maximum)."* |

**Code Coverage Comparison**

| Code | Drug Classes | UHC | Cigna |
|------|--------------|-----|-------|
| G0480 | 1-7 classes | Covered | Covered |
| G0481 | 8-14 classes | Covered | Limited |
| G0482 | 15-21 classes | Covered | **NOT Covered** |
| G0483 | 22+ classes | Covered | **NOT Covered** |

**Recommendation**

| Item | Details |
|------|---------|
| **Peer Practice** | Cigna limits definitive testing to 7-8 drug classes; G0482/G0483 denied |
| **Exploitation Risk** | Providers upcode to G0483 (highest reimbursement) when G0480 sufficient |
| **Suggested Action** | Consider drug class limits or prior auth for G0482/G0483 |

**Suggested Policy Language**

> **Definitive Drug Testing Limits**
> 
> UnitedHealthcare considers definitive drug testing of more than 14 drug classes per date of service (G0482, G0483) to require documentation of medical necessity. Claims for G0482 or G0483 may be subject to medical review and may be denied or downcoded if documentation does not support the expanded testing panel.

**Denial Code:** `DT-CLASS-LIMIT`

---

## 2. G0659 Coverage Restriction

**Source Text Comparison**

| UHC (2025R6005B) | Cigna |
|------------------|-------|
| *G0659 listed as covered definitive testing code* | *"G0480 or G0659 is not covered or reimbursable."* |

**Recommendation**

| Item | Details |
|------|---------|
| **Peer Practice** | Cigna excludes G0659 from coverage entirely |
| **Exploitation Risk** | G0659 may be billed alongside other definitive tests for additional revenue |
| **Suggested Action** | Require medical necessity documentation for G0659 |

**Suggested Policy Language**

> **G0659 Medical Necessity Requirement**
> 
> G0659 (definitive drug testing utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers) requires documentation of medical necessity demonstrating specific clinical need for structural isomer differentiation.

**Denial Code:** `DT-G0659-MN`

---

## 3. Annual Frequency Limits

**Source Text Comparison**

| UHC (2025R6005B) | Cigna/Industry |
|------------------|----------------|
| *No annual frequency limits specified. Policy addresses daily limits only.* | *"Reasonable and necessary to perform POC testing up to 12 times annually. More than 12 times annually may be denied if not deemed medically necessary."* |

**Recommendation**

| Item | Details |
|------|---------|
| **Peer Practice** | 12 presumptive tests annually considered reasonable |
| **Exploitation Risk** | High-volume clinics may test 24-52 times annually without limits |
| **Suggested Action** | Implement annual frequency limits with medical necessity review |

**Suggested Policy Language**

> **Annual Drug Testing Frequency**
> 
> UnitedHealthcare considers up to 12 presumptive drug tests and up to 12 definitive drug tests per member per calendar year to be reasonable and medically necessary for routine monitoring. Testing frequency exceeding these limits may be subject to medical review.

**Denial Code:** `DT-FREQ-LIMIT`

---

## 4. Step-Therapy Testing Approach

**Source Text Comparison**

| UHC (2025R6005B) | Cigna/Industry |
|------------------|----------------|
| *"A presumptive drug test is not required to be provided prior to a definitive drug test."* | *Clinical guidelines recommend step-therapy: presumptive first, definitive confirmation only when clinically indicated.* |

**Recommendation**

| Item | Details |
|------|---------|
| **Peer Practice** | ASAM/SAMHSA guidelines recommend presumptive screening before definitive |
| **Exploitation Risk** | Providers skip presumptive and bill expensive definitive directly (DT-FT008) |
| **Suggested Action** | Add guidance encouraging step-therapy approach |

**Suggested Policy Language**

> **Testing Sequence Guidance**
> 
> While a presumptive drug test is not required prior to definitive testing, UnitedHealthcare considers presumptive screening followed by selective definitive confirmation to be the clinically appropriate approach. Definitive testing without presumptive screening may be subject to medical necessity review.

**Review Flag:** `DT-STEP-THERAPY`

---

## 5. Random vs. Routine Testing Guidance

**Source Text Comparison**

| UHC (2025R6005B) | Cigna/Industry |
|------------------|----------------|
| *No guidance on random vs. routine testing patterns.* | *"Testing should be performed randomly. Routine testing at each office visit is not considered random and may result in denial."* |

**Recommendation**

| Item | Details |
|------|---------|
| **Peer Practice** | Random testing recommended; routine every-visit testing flagged |
| **Exploitation Risk** | Pattern billing - testing at every visit regardless of clinical need |
| **Suggested Action** | Add random testing guidance with pattern analysis |

**Suggested Policy Language**

> **Drug Testing Pattern Guidance**
> 
> For chronic pain management and substance abuse monitoring, drug testing should be performed on a random basis rather than routinely at each office visit. Providers demonstrating testing patterns significantly exceeding random frequency expectations may be subject to utilization review.

**Review Flag:** `DT-PATTERN-REVIEW`

---

## Implementation Summary

| Rule | Denial/Review Code | Action |
|------|-------------------|--------|
| Drug Class Limit | DT-CLASS-LIMIT | Add limits or prior auth for G0482/G0483 |
| G0659 Coverage | DT-G0659-MN | Require medical necessity documentation |
| Annual Frequency | DT-FREQ-LIMIT | Implement 12/year limit with review |
| Step-Therapy | DT-STEP-THERAPY | Add guidance, flag definitive-only claims |
| Random Testing | DT-PATTERN-REVIEW | Add pattern analysis for high-frequency providers |

---

**Sources:**
- [UHC Drug Testing Policy 2025R6005B](https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-reimbursement/COMM-Drug-Testing-Policy.pdf)
- [Cigna R25 Drug Testing](https://static.cigna.com/assets/chcp/secure/pdf/resourceLibrary/clinReimPolsModifiers/R25_Drug_Testing_Billing_Requirements.pdf)
- [Cigna Coverage Policy mm_0513](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/medical/mm_0513_coveragepositioncriteria_drug_test.pdf)
- [AAPC Forum - Cigna Drug Testing](https://www.aapc.com/discuss/threads/definitive-drug-testing-for-cigna.133736/)
